Gerald P Linette

List of Publications by Year
in descending order

29 papers	5,568 citations	471509 17 h-index	501196 28 g-index
29 all docs	29 docs citations	29 times ranked	9981 citing authors

#	Article	IF	Citations
1	BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced *BRAFV600*-mutant Melanoma. Clinical Cancer Research, 2022, 28, 1098-1106.	7.0	32
2	On the Twentieth Anniversary of Dendritic Cell Vaccines â€" Riding the Next Wave. Cancer Research, 2022, 82, 966-968.	0.9	4
3	Health-related quality of life in patients with malignant melanoma by stage and treatment status. Journal of the American Academy of Dermatology, 2021, 85, 486-489.	1.2	2
4	Preclinical evaluation of cancer immune therapy using patientâ€derived tumor antigenâ€specific T cells in a novel xenograft platform. Clinical and Translational Immunology, 2021, 10, e1246.	3.8	4
5	Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature Communications, 2021, 12, 4365.	12.8	53
6	Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments. , 2021, 9, e003148.		18
7	Primary Bone Tumors: Challenges and Opportunities for CAR-T Therapies. Journal of Bone and Mineral Research, 2019, 34, 1780-1788.	2.8	12
8	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nature Medicine, 2019, 25, 454-461.	30.7	466
9	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23662-23670.	7.1	40
10	RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. Journal of Neuro-Oncology, 2019, 141, 95-102.	2.9	5
11	CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro-Oncology, 2018, 20, 1429-1438.	1.2	197
12	Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIBâ€"IVM1c melanoma. Melanoma Research, 2018, 28, 44-51.	1.2	31
13	CAR T-Cell Therapies in Glioblastoma: A First Look. Clinical Cancer Research, 2018, 24, 535-540.	7.0	103
14	18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.. Journal of Clinical Oncology, 2018, 36, 192-192.	1.6	11
15	Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe. Journal of Investigative Dermatology, 2017, 137, 1370-1372.	0.7	54
16	TRPM1 (melastatin) expression is an independent predictor of overall survival in clinical AJCC stage I and II melanoma patients. Journal of Cutaneous Pathology, 2017, 44, 328-337.	1.3	13
17	Neoantigen Vaccines Pass the Immunogenicity Test. Trends in Molecular Medicine, 2017, 23, 869-871.	6.7	45
18	Management Controversies in Head and Neck Melanoma. JAMA Facial Plastic Surgery, 2017, 19, 53-62.	2.1	19

#	ARTICLE	IF	CITATIONS
19	Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy.. Journal of Clinical Oncology, 2017, 35, 80-80.	1.6	2
20	Use of targeted next generation sequencing (NGS) to assess mutational load in glioblastoma (GBM).. Journal of Clinical Oncology, 2017, 35, 2027-2027.	1.6	1
21	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 1374-1385.	10.7	1,034
22	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology, The, 2016, 17, 1558-1568.	10.7	827
23	pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Medicine, 2016, 8, 11.	8.2	350
24	A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science, 2015, 348, 803-808.	12.6	1,139
25	Dendritic cell-based vaccines. OncoImmunology, 2013, 2, e26512.	4.6	15
26	Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood, 2013, 122, 863-871.	1.4	932
27	IL-12p70â€"producing patient DC vaccine elicits Tc1-polarized immunity. Journal of Clinical Investigation, 2013, 123, 3383-3394.	8.2	137
28	Amino-Terminal Extended Peptide Single-Chain Trimers Are Potent Synthetic Agonists for Memory Human CD8+ T Cells. Journal of Immunology, 2012, 188, 5839-5849.	0.8	5
29	Biomarkers in melanoma: Stage III and IV disease. Expert Review of Molecular Diagnostics, 2005, 5, 65-74.	3.1	17